Opioid and benzodiazepine requirements in neonatal and pediatric patients undergoing venoarterial ECMO: insights from a predominantly cardiac cohort - Takeaways - MDSpire

Sedation and Analgesic Use of Opioids and Benzodiazepines in Neonates and Children on Venoarterial ECMO: Findings from a Primarily Cardiac Patient Group

  • By

  • Somayah A. Alsuhaibani

  • Ashjan F. Alghanem

  • Ibrahim A. Alredaini

  • Shaimaa Alsulami

  • Luluah A. AlTukhaifi

  • Reem M. Beheri

  • Mashael AlFaifi

  • Renad A. Alshuraim

  • Lama Alfehaid

  • Khalid Al Sulaiman

  • July 21, 2026

Share

  • 1

    The study analyzed sedation and analgesic use in 80 neonates and pediatric patients on venoarterial ECMO from 2019 to 2023.

  • 2

    All patients received opioids, and 96.3% received benzodiazepines, with median cumulative exposures of 7.33 mg/kg and 15.75 mg/kg, respectively.

  • 3

    Longer ICU stays and ECMO durations were linked to increased cumulative opioid exposure, with significant coefficients indicating strong associations.

  • 4

    Higher average opioid doses, acute kidney injury, and prolonged ICU and ECMO durations were predictors of increased in-hospital mortality.

  • 5

    The findings emphasize the need for individualized sedation strategies to optimize outcomes in critically ill neonates and pediatric patients.

Original Source(s)

Related Content